Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 8/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487118 | 0.91 | FGFR4 (0.67) | FGFR4HDAC6FGFR1FGFR2FGFR3 | |
| SCHEMBL4483401 | 0.90 | HDAC6 (0.59) | FGFR4HDAC6FGFR1FGFR2FGFR3 | |
| SCHEMBL4483026 | 0.89 | FGFR4 (0.65) | FGFR4HDAC6FGFR1FGFR2FGFR3 | |
| SCHEMBL4493535 | 0.88 | HDAC6 (0.62) | FGFR4HDAC6FGFR1FGFR2FGFR3 | |
| SCHEMBL4489000 | 0.87 | HDAC6 (0.57) | FGFR4HDAC6FGFR1FGFR2FGFR3 | |
| SCHEMBL4492371 | 0.87 | HDAC6 (0.71) | FGFR4HDAC6FGFR1FGFR2FGFR3 | |
| SCHEMBL4480163 | 0.87 | FGFR4 (0.68) | FGFR4HDAC6FGFR1FGFR2FGFR3 | |
| SCHEMBL4489393 | 0.86 | HDAC6 (0.60) | FGFR4HDAC6FGFR1FGFR2FGFR3 | |
| SCHEMBL4502319 | 0.86 | HDAC6 (0.67) | FGFR4HDAC6FGFR1FGFR2FGFR3 | |
| SCHEMBL4482955 | 0.84 | HDAC6 (0.62) | FGFR4HDAC6FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | claimed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | FGFR4 257/4885HDAC6 3478/4885FGFR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.